Xilio Therapeutics (XLO) Stock Price, News & Analysis

Company Overview

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $0.72 to $0.72
• 50-Day Range: $0.65 to $0.74
• 52-Week Range: $0.62 to $1.70
• Volume: 4,859 shs
• Average Volume: 1.99 million shs
• Market Capitalization: $37.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Buy

Xilio Therapeutics Stock Analysis - MarketRank™

Xilio Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 503rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Xilio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Xilio Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Xilio Therapeutics are expected to grow in the coming year, from ($1.14) to ($0.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Xilio Therapeutics is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xilio Therapeutics is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xilio Therapeutics has a P/B Ratio of 5.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.46% of the float of Xilio Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Xilio Therapeutics has a short interest ratio ("days to cover") of 7.5.

Change versus previous month

Short interest in Xilio Therapeutics has recently increased by 12.83%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xilio Therapeutics does not currently pay a dividend.

Dividend Growth

Xilio Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

23.46% of the float of Xilio Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Xilio Therapeutics has a short interest ratio ("days to cover") of 7.5.

Change versus previous month

Short interest in Xilio Therapeutics has recently increased by 12.83%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.38

News Sentiment

Xilio Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Xilio Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for XLO on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

1 people have added Xilio Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Xilio Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $72,977.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 6.30% of the stock of Xilio Therapeutics is held by insiders.

Percentage Held by Institutions

54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XLO Stock Analysis - Frequently Asked Questions

How have XLO shares performed this year?

Xilio Therapeutics' stock was trading at $0.9550 at the beginning of 2025. Since then, XLO shares have decreased by 24.2% and is now trading at $0.7238.

How were Xilio Therapeutics' earnings last quarter?

Xilio Therapeutics, Inc. (NASDAQ:XLO) issued its quarterly earnings results on Thursday, August, 14th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.08. The business had revenue of $8.21 million for the quarter, compared to analysts' expectations of $8.21 million. Xilio Therapeutics had a negative net margin of 374.79% and a negative trailing twelve-month return on equity of 399.15%.

When did Xilio Therapeutics IPO?

Xilio Therapeutics (XLO) raised $125 million in an IPO on Friday, October 22nd 2021. The company issued 7,353,000 shares at a price of $16.00-$18.00 per share.

Who are Xilio Therapeutics' major shareholders?

Xilio Therapeutics' top institutional shareholders include Bridgeway Capital Management LLC (0.11%). Insiders that own company stock include Gilead Sciences, Inc, Venture Fund Xi LP Atlas, Rene Russo, James Samuel Shannon, Christopher James Frankenfield and Kevin M Brennan.
View institutional ownership trends.

How do I buy shares of Xilio Therapeutics?

Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Xilio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Xilio Therapeutics investors own include PayPal (PYPL), Achilles Therapeutics (ACHL), JPMorgan Chase & Co. (JPM), AT&T (T), United Microelectronics (UMC), Adverum Biotechnologies (ADVM) and atai Life Sciences (ATAI).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/04/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XLO
• CIK: 1840233
• Web: www.xiliotx.com
• Phone: 857-524-2466
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Xilio Therapeutics: $3.00
• High Price Target: $4.00
• Low Price Target: $2.00
• Potential Upside/Downside: +314.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.24 million
• Net Margins: -374.79%
• Pretax Margin: -374.79%
• Return on Equity: -399.15%
• Return on Assets: -58.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.32
• Quick Ratio: 2.32

Sales & Book Value

• Annual Sales: $6.34 million
• Price / Sales: 5.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.14 per share
• Price / Book: 5.17

Miscellaneous

• Outstanding Shares: 51,830,000
• Free Float: 48,563,000
• Market Cap: $37.51 million
• Optionable: Not Optionable
• Beta: -0.14